June 15–16, 2020 | 11:00AM–3:30PM ET | 3:00–7:30PM UTC | 5:00–9:30PM CEST*
*Program is subject to change
Journal of Experimental Medicine (JEM) publishes papers providing novel conceptual insight into immunology, neuroscience, cancer biology, vascular biology, microbial pathogenesis, and stem cell biology. All editorial decisions are made by active scientists in conjunction with professional editors. JEM was established in 1896. Carl Nathan and Michel Nussenzweig serve as JEM Editorial Board Co-Chairs. Dr. Nathan is the R.A. Rees Pritchett Professor and Chairman of the Department of Microbiology and Immunology at Weill Cornell Medicine. Dr. Nussenzweig is the Zanvil A. Cohn and Ralph M. Steinman Professor at The Rockefeller University, Investigator at Howard Hughes Medical Institute, and Senior Physician. Teodoro Pulvirenti serves as JEM Executive Editor. Learn more about JEM editors.
Editors attending this meeting
Gaia Trincucci, Scientific Editor
Gaia received her PhD in Cell Biology from the University of Basel, Switzerland, studying the role of Type III interferons in chronic hepatitis C. She pursued her postdoctoral work with Abraham Brass and Kate Fitzgerald at University of Massachusetts Medical School, focusing on uncovering novel host factors in viral replication. She joined the Journal of Experimental Medicine as a Scientific Editor in 2018. Gaia is in charge of JEM Viewpoints.
Email Gaia to discuss your research: email@example.com
Teodoro Pulvirenti, Executive Editor, JEM; Director of Editorial Development, RUP
Teodoro (Teo) received his PhD from the Mario Negri Sud Institute in Italy. He then carried out his postdoctoral work in the lab of Alan Hall at Memorial Sloan Kettering Cancer Center, studying the role of Wnt signaling in cancer stem cells, and continued this line of research in the lab of Eric Holland at the same institution. Teo started his editorial career at the Journal of Experimental Medicine (JEM) in 2013. He then joined Nature Cell Biology as Senior Editor, and returned to JEM as Executive Editor in 2016. He is also the Director of Editorial Development for Rockefeller University Press.
JEM Articles related to COVID-19 / SARS-CoV-2
Viewpoint | March 30, 2020
Forty years with coronaviruses
Susan R. Weiss
Editorial | March 31, 2020
We are here for you and ready to hear from you
Carl F. Nathan, Michel C. Nussenzweig, Teodoro Pulvirenti
Viewpoint | April 14, 2020
COVID-19 and emerging viral infections: The case for interferon lambda
Ludmila Prokunina-Olsson, Noémie Alphonse, Ruth E. Dickenson, Joan E. Durbin, Jeffrey S. Glenn, Rune Hartmann, Sergei V. Kotenko, Helen M. Lazear, Thomas R. O'Brien, Charlotte Odendall, Olusegun O. Onabajo, Helen Piontkivska, Deanna M. Santer, Nancy C. Reich, Andreas Wack, Ivan Zanoni
Perspective | April 16, 2020
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Betsy J. Barnes, Jose M. Adrover, Amelia Baxter-Stoltzfus, Alain Borczuk, Jonathan Cools-Lartigue, James M. Crawford, Juliane Daßler-Plenker, Philippe Guerci, Caroline Huynh, Jason S. Knight, Massimo Loda, Mark R. Looney, Florencia McAllister, Roni Rayes, Stephane Renaud, Simon Rousseau, Steven Salvatore, Robert E. Schwartz, Jonathan D. Spicer, Christian C. Yost, Andrew Weber, Yu Zuo, Mikala Egeblad
Perspective | April 30, 2020
The many faces of the anti-COVID immune response
Santosha A. Vardhana and Jedd D. Wolchok
Why submit your research to JEM?
At JEM, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. JEM implements editorial policies with highly productive investigators in mind.
Format Neutral: You may submit your papers in ANY format.
Transfer Policy: We welcome submissions that include reviewer comments from another journal. You may also request manuscript transfer between Rockefeller University Press journals, and we can confidentially send reviewer reports and identities to another journal beyond RUP.
Fair and Fast: We limit rounds of revision, and we strive to provide clear, detailed decisions that illustrate what is expected in the revisions. Articles appear online one to two days after author proofs are returned.
Open Access Options: Our options include Immediate Open Access (CC-BY) and open access six months after publication (CC-BY-NC-SA).
EMBO Molecular Medicine is the top open access journal in the field of experimental medicine dedicated to science at the interface between translational and clinical research and basic life sciences. The journal welcomes original studies performed in cells and/or animals provided that they demonstrate evident human disease relevance. Submission of first-in-human studies and analyses of patient samples are also encouraged.
The journal is one of four EMBO Press journals run by in-house professional scientific editors. EMBO Molecular Medicine is supported by academic Chief Editor, Prof. Philippe Sansonetti, nine academic Senior Editors and a broad and diverse advisory editorial board. Click here to learn more about the editors and the topics covered in the journal.
Céline Carret, Senior Scientific Editor
Céline Carret completed her PhD at the University of Montpellier, France, characterising host immunodominant antigens to fight babesiosis, a parasitic disease caused by a unicellular Apicomplexan parasite closely related to the malaria agent Plasmodium. She further developed her post-doctoral career on malaria working at the Wellcome Trust Sanger Institute in Cambridge, UK and Instituto de Medicina Molecular in Lisbon, Portugal. Céline joined EMBO Molecular Medicine as a Scientific Editor in March 2011.
Email Céline to discuss your research: firstname.lastname@example.org
Zeljko Durdevic, Scientific Editor
Zeljko received his PhD from the University of Heidelberg / German Cancer Research Center, where he investigated the function of DNA methyltransferase 2 uncovering that this enzyme plays important roles in innate immunity, stress responses and genome stability. He carried out his postdoctoral research in the laboratory of Anne Ephrussi at EMBL, where he focused on the role of the RNA helicase Vasa in germ cell lineage homeostasis and genome stability. Zeljko joined EMBO Molecular Medicine as a Scientific Editor in January 2020.
Email Zeljko to discuss your research: email@example.com
Interview | 24 April 2020
Interview with Akiko Iwasaki, Gérard Krause, Samuel Alizon, and Rino Rappuoli
Celine K Carret
Commentary | 28 April 2020
Akiko Iwasaki, Nathan D Grubaugh
Editorial | 4 May 2020
Philippe J Sansonetti
Commentary | 5 May 2020
Virginia Quaresima, Matteo M Naldini, Daniela M Cirillo
Article | 19 May 2020
Tao Liu, Jieying Zhang, Yuhui Yang, Hong Ma, Zhenyu Li, Jiaoyue Zhang, Ji Cheng, Xiaoyun Zhang, Yanxia Zhao, Zihan Xia, Liling Zhang, Gang Wu, Jianhua Yi
Commentary | 25 May 2020
Evangelos Andreakos, Sotirios Tsiodras
Commentary | 26 May 2020
Opinion | 26 May 2020
Jose A. Bengoechea, Connor G.G. Bamford
Correspondence | 27 May 2020
Syril D Pettit, Keith R Jerome, David Rouquié, Bernard Mari, Pascal Barbry, Yasunari Kanda, Mineo Matsumoto, Susan Hester, Leah Wehmas, Jason W Botten, Emily A Bruce
The Journal of Clinical Investigation (JCI), established in 1924 and published by the American Society for Clinical Investigation, is a peer-reviewed journal publishing discoveries in basic and clinical biomedical science that will advance the practice of medicine. Research of interest spans all biomedical specialties, including infectious diseases, immunology, autoimmunity, gastroenterology, metabolism, nephrology, neuroscience, oncology, cardiology, and others. The JCI also publishes reviews, commentaries, viewpoints, editorials, and feature items. The editorial board, based at Johns Hopkins University, is led by editor-in-chief Rexford S. Ahima and supported by Executive Editor Sarah Jackson and Science Editors Corrine Williams, Elyse Dankoski, and Lisa Conti. Contact the editors at firstname.lastname@example.org.
All research published in the JCI is freely available immediately upon publication on the journal’s website and is also deposited in PubMed Central. The journal is supported by publication fees and meets mandates from funding agencies (including Wellcome) for open access publication. Learn more about submitting your paper to the JCI.
Recently published COVID-19 articles in the JCI:
Alessio Mazzoni, … , Francesco Annunziato, Lorenzo Cosmi
Clinical Medicine, Published May 28, 2020
Mark P. Breazzano, … , Alice Chen-Plotkin, Royce W.S. Chen
Clinical Medicine, Published May 28, 2020
Wen-Chao Song, Garret A. FitzGerald
Viewpoint, Published May 27, 2020
Evelyne Bischof, … , Jeannette Wolfe, Sabra L. Klein
Viewpoint, Published May 11, 2020
Barney S. Graham, Kizzmekia S. Corbett
Viewpoint, Published April 30, 2020
Maximilian F. Konig, … , Shibin Zhou, Chetan Bettegowda
Viewpoint, Published April 30, 2020
Arthur L. Caplan, Ross Upshur
Viewpoint, Published April 24, 2020
Evan M. Bloch, … , Jeffrey A. Bailey, Aaron A.R. Tobian
Review, Published April 7, 2020
Viewpoint, Published April 6, 2020
M. Bishr Omary, … , Reynold A. Panettieri Jr., Kathleen W. Scotto
Viewpoint, Published April 3, 2020
Viewpoint, Published March 30, 2020
Savannah F. Pedersen, Ya-Chi Ho
Commentary, Published March 27, 2020
Guang Chen, … , Jianping Zhao, Qin Ning
Clinical Medicine, Published March 27, 2020
Rexford S. Ahima, … , Donna M. Martin, Pavan Reddy
Editorial, Published March 23, 2020
Arturo Casadevall, Liise-anne Pirofski
Viewpoint, First published March 13, 2020
The editors of JCI and JCI Insight have revised the editorial process to address the impact of the COVID-19 pandemic on the global research community. Highlights:
Frontiers is an award-winning Open Science platform and leading Open Access scholarly publisher. Our mission is to make research results openly available to the world, thereby accelerating scientific and technological innovation, societal progress and economic growth. Covering more than 600 academic disciplines, our 80+ journals are led and peer-reviewed by editorial boards of over 100,000 top researchers.
Recognizing the exceptional nature of the COVID-19 pandemic, Frontiers has established a priority peer-review process and waived Article Processing Charges (APCs) until 31 July 2020 for manuscripts submitted in response to the pandemic. We particularly encourage researchers to launch and contribute to Research Topics on coronavirus: highly visible article collections showcasing emerging and important areas of COVID-19 research across multiple disciplines.
Denise Doolan, Specialty Chief Editor, Frontiers in Immunology - Vaccines and Molecular Therapeutics
Professor Denise Doolan is Deputy Director of the Australian Institute of Tropical Health & Medicine (AITHM) at James Cook University, Australia. A molecular immunologist, her research focuses on developing novel immunotherapeutics and immunodiagnostics for complex pathogens that cause chronic diseases, using malaria as a model. Much of her career has focused on malaria immunology and vaccine development. Most recently, she is moving into the area that intersects infectious and chronic disease.
Alessandra Fornarelli, Journal Manager, Frontiers in Immunology
Alessandra Fornarelli graduated from the University of Piemonte Orientale in Novara, Italy, and completed a doctoral degree at the University of Bonn, Germany, working at the German Center for Neurodegenerative diseases (DZNE) in the laboratory led by Professor Pierluigi Nicotera. She joined Frontiers in 2016, working on several journals before becoming journal manager for Frontiers in Immunology in January 2018.
Email Alessandra to discuss your research: email@example.com
COVID-19: Pathophysiology, epidemiology, clinical management and public health response
163 articles | Led by Denise Doolan & 12 other leading researchers
Interdisciplinary research addressing knowledge gaps and generating evidence for the improved management and control of COVID-19, with scientific contributions from all areas of virology, immunology, clinical microbiology, epidemiology, therapeutics, communications as well as infection prevention and public health risk assessment and management studies.
COVID-19: Molecular mechanisms, translational approaches and therapeutics
Open for submissions | Led by José A G Agúndez & 20 leading researchers
Aims to highlight advances in the clinical diagnosis of COVID-19, molecular mechanisms and pathology of the disease in different populations, therapeutic target identification, and drug and vaccine development towards patient treatment and prevention of disease.
Control of vaccine-preventable diseases across the whole of life
Open for submissions | Led by Chandini Raina MacIntyre & Daniel A Salmon
Seeks manuscripts on pediatric and adult vaccine-preventable diseases, as well as vaccines for emerging and re-emerging infectious diseases including COVID-19. Methodologies can include epidemiology, public health, clinical trials, mathematical modelling, health economic modelling, and social or behavioral research.
Open for submissions | Led by Ada Maria De Barcelos Alves, Silvia Beatriz Boscardin & Annie Elong Ngono
Welcomes original research, reviews, opinion and perspective articles on DNA vaccines for prevention against infection by pathogens, treatment of different diseases, understanding the mechanisms involved in the activation of immune responses elicited by these vaccines, improvement in vivo transfection, and antigen expression.
Frontiers’ Research Topics are peer-reviewed article collections around cutting-edge research themes. Defined, managed and led by renowned researchers, they unite the world’s leading experts around the hottest topics, stimulating collaboration and accelerating science. Managed and disseminated on Frontiers’ Open Science platform, these collections are free to access and highly visible, increasing readership and citations for your research.